-
Company Insights
Innovation and Patenting activity of Sierra Oncology Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Sierra Oncology Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Sierra Oncology Inc – Company Profile
Sierra Oncology Inc (Sierra Oncology), formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company’s product candidate includes SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. Sierra Oncology also develops SRA141, a small molecule inhibitor of the cell division cycle 7 kinase. The company offers DNA damage response services such as cellular pathways, monitoring, signalling, and repairing DNA damage. Sierra Oncology...
Add to Basket -
Product Insights
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. Its phosphorylate substrates regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors. The Cell Division Cycle 7-related Protein Kinase pipeline drugs market research report provides comprehensive information on the therapeutics under development for Cell Division Cycle 7-related Protein Kinase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA),...
-
Product Insights
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. Symptoms include heart attack, stroke, deep venous thrombosis, headaches, lack of concentration, and fatigue. The Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline drugs market research report provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug...
-
Product Insights
Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Peritoneal cancer develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus, and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea, and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological...
-
Product Insights
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. The Bromodomain-containing protein 4 - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Bromodomain-containing protein 4, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration...
-
Product Insights
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Tyrosine Protein Kinase JAK1 pipeline market research report provides comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in...
-
Product Insights
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Tyrosine Protein Kinase JAK2 pipeline market research report provides comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in...
-
Product Insights
Prostate Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020
Prostate Cancer Diagnostic Tests include assays of mostly antibodies released in response to a prostate cancer and cancer-causing proteins. GlobalData's Medical Devices sector report, “Prostate Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Prostate Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Prostate Cancer Diagnostic Tests Pipeline Assessment report provides key information and data related to: Extensive...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...